Abstract
Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have